Divi's Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Divi's Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹50 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹49 tied up three years earlier. More money tied up than 91% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 90% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 89% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹89Over the last 3 years, every ₹100 of reported profit came with ₹89 of operating cash.
Lower than 62% of Healthcare companies in India.
Self-Funding Ratio
1.1×Over the last 3 years its own operating cash covered its investment spending (capex) 1.1 times.
Lower than 60% of Healthcare companies in India.
Cash Locked Ratio
₹50For every ₹100 of sales, ₹50 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹49 tied up three years earlier.
More money tied up than 91% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹26Sales grew 37% in 3 years; of every extra ₹100 of sales, ₹26 became extra profit.
Higher than 73% of Healthcare companies in India.
Asset Productivity Ratio
+37% / +39%In 3 years sales changed by +37% while total assets changed by +39%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 67% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 89% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 90% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Divi's Laboratories Limited owes ₹0.16 for every ₹1 it owns. Net profit rose 17% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
83.1Investors pay ₹83.1 for every ₹1 of Divi's Laboratories Limited's yearly profit, higher than 88% of Healthcare companies in India.
P/B ratio
14.51The share price is 14.51 times Divi's Laboratories Limited's book value per share, higher than 93% of Healthcare companies in India.
Market cap
₹243,222 CrThe total market value of all of Divi's Laboratories Limited's shares at today's price (share price × number of shares), larger than almost all Healthcare companies in India. PosiCap size class: Tito Cap.
Net worth (book value)
₹16,761 CrWhat Divi's Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹631.37Net worth divided by the number of shares. The share price of ₹9,162 is 14.5 times this, which is the P/B above.
Return on equity (ROE)
17.5%Divi's Laboratories Limited earned 17.5% on its shareholders' money over the last year, higher than 71% of Healthcare companies in India.
Owes vs Owns
0.16×Divi's Laboratories Limited owes ₹0.16 for every ₹1 it owns (low), lower than 90% of Healthcare companies in India.
Dividend yield
0.32%Divi's Laboratories Limited pays 0.32% of its share price as dividends a year, lower than 56% of dividend-paying Healthcare companies in India.
Revenue growth
+12%Revenue rose 12% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit growth
+17%Net profit rose 17% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Profit margin
24.5%Divi's Laboratories Limited keeps ₹25 of every ₹100 of revenue as net profit.
Cash quality
1.07×Cash from Divi's Laboratories Limited's business was 1.07× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
129.5×Divi's Laboratories Limited's operating profit covered its interest costs 129.5 times in the year to Mar 2026.
Cash vs debt
Net cashDivi's Laboratories Limited held ₹3,229 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Divi's Laboratories Limited's P/E ratio?
Investors pay ₹83.1 for every ₹1 of Divi's Laboratories Limited's yearly profit, higher than 88% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Divi's Laboratories Limited: ₹243,222 Cr ÷ ₹16,761 Cr (31 Mar 2026) = 14.5.
What is Divi's Laboratories Limited's return on equity?
Divi's Laboratories Limited earned 17.5% on its shareholders' money over the last year, higher than 71% of Healthcare companies in India.
How much does Divi's Laboratories Limited owe compared with what it owns?
Divi's Laboratories Limited owes ₹0.16 for every ₹1 it owns (low), lower than 90% of Healthcare companies in India.
Does Divi's Laboratories Limited pay a dividend?
Yes. Divi's Laboratories Limited pays 0.32% of its share price as dividends a year, lower than 56% of dividend-paying Healthcare companies in India.
Is Divi's Laboratories Limited's revenue growing?
Revenue rose 12% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.